Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe

Glargine plus Lixisenatide or vildagliptin succeeding to BOT T2DM control evaluation trial in Kobe - GLP-ONE KOBE study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010769

Enrollment

100

Registered

2013-06-15

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

T2DM

Interventions

Basal Insulin+Lixisenatide Basal Insulin+vildagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Sub-optimal controlled T2DM treated with basal insulin and Sitagliption (-/+ oher OHA)(HbA1c 7%-10%))

Exclusion criteria

Exclusion criteria: Renal or Liver dysfunction Pregnant or breast-feeding women Slowly progressive T1DM

Design outcomes

Primary

Measure	Time frame
Improvement of HbA1c Improvement daily BG profile	—

Countries

Japan

Contacts

Public ContactSakaguchi kazuhiko

Kobe University Graduate school of medicine diabetes and endocrinology

kzhkskgc@med.kobe-u.ac.jp078-382-5861

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026